Literature DB >> 7840349

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

M H Kronig1, R A Munne, S Szymanski, A Z Safferman, S Pollack, T Cooper, J M Kane, J A Lieberman.   

Abstract

OBJECTIVE: The purpose of this study was to determine if plasma clozapine levels were associated with treatment response.
METHOD: To examine this question, neuroleptic nonresponsive patients with schizophrenia or schizoaffective disorder were given clozapine, which was titrated to 500 mg/day by day 14 of treatment, and the dose was held fixed at least through day 21. Subsequently, clozapine doses were adjusted as clinically indicated, up to a maximum of 900 mg/day. Plasma clozapine levels were obtained at weeks 3 and 6, and standard clinical ratings (Brief Psychiatric Rating Scale [BPRS] and Clinical Global Impression) were done at baseline and at weeks 3 and 6.
RESULTS: Data from 45 subjects were analyzed. There were no correlations between plasma clozapine levels and change in BPRS scores at treatment weeks 3 and 6. However, when the subjects were classified as responders or nonresponders, therapeutic response was associated with clozapine blood levels above 350 ng/ml.
CONCLUSIONS: This study suggest that clozapine blood levels are correlated with clinical response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840349     DOI: 10.1176/ajp.152.2.179

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  34 in total

Review 1.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

2.  Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study.

Authors:  K H Kho; B A Blansjaar; S de Vries; D Babuskova; A H Zwinderman; D H Linszen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 3.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 4.  Clozapine dose for schizophrenia.

Authors:  Selvizhi Subramanian; Birgit A Völlm; Nick Huband
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

5.  Clozapine and some other antipsychotic drugs may preferentially block the same subset of GABA(A) receptors.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

Review 6.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

Review 7.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996

Review 8.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 9.  What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Authors:  Peter Schulte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study.

Authors:  C Nordin; B Almé; U Bondesson
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.